Close
RNS Number : 7752B
ValiRx PLC
25 September 2018
 

 

 

 

 

VALIRX PLC

("ValiRx", "the Company" or "the Group")

 

HALF YEARLY REPORT FOR THE PERIOD ENDED 30 JUNE 2018

 

London, UK., 25 September 2018: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, today announces its Half Yearly Report for the period ended 30 June 2018.

 

HIGHLIGHTS

Operational Highlights

·     Final results from VAL401's Phase II Clinical Trial in patients with lung cancer show verified trial data offering palliative stage patients an improvement in life quality alongside survival prospects with confirmation of acceptance of the Clinical Study Report received post period (announced 06/09/18);

·     Receipt of MHRA approval to escalate and extend dosing in VAL201's Phase l/ll Clinical Trial to treat prostate cancer - Recruitment of patients for this second phase is continuing - A post period preliminary inspection of the clinical data derived from the original dosing regimen has been completed, which highlights a dose-related impact on patients' physiology and chemistry;

·   VAL301 is in late pre-clinical phase initially for the treatment of the gynaecological condition, endometriosis.  This treatment will be a reformulation of VAL201, which pre-clinical studies suggest does not compromise bone density or fertility.  Final laboratory tests are underway prior to advancing the VAL301 compound into additional toxicology and then clinical trials;

·   An optimized, commercially viable, 2nd generation development of the VAL101 molecule has been created.  The compound is derived from ValiRx's proprietary GeneICE platform to shut down rebellious genes causing cancer and potentially some neurological disorders.  Preparation is underway for the compound's entry into the clinic; and

·    The period saw further strengthening of ValiRx's patent portfolio in the US, Europe & New Zealand augmented by a post-period grant of a US Patent for VAL301.

 

 

Financial Highlights

·      ValiRx received R&D Tax Credits amounting to c. £416,000 in September 2018

·      Loss before income taxation increased slightly by 4.75% to £2,155,788 (H1 2017: £2,054,211)

·      Total comprehensive loss for the period of £1,914,453 (H1 2017: £1,800,092); and

·      Cash and cash equivalents as at 30 June 2018 of £590,615 (H1 2017: £383,426).

 

Post-Period highlights

·      Placing to raise £1.15m of gross proceeds in September 2018 with existing and new investors;

·      Detailed discussions are in progress in respect to a pivotal Phase III Clinical Trial for VAL401.  Partners external to ValiRx and ValiSeek will have substantial input into the trial design, with first dosing anticipated next year.  An Advisory board of UK Key Opinion Leaders expressed confidence in taking VAL401 immediately, alongside standard of care cancer treatment.

 

 

Oliver de Giorgio-Miller, Non-Executive Chairman of ValiRx, commented:

"The past six months have been a pivotal period for the Company as we have seen our two clinical stage compounds reach respective inflection points on their developmental pathways and our pre-clinical portfolio of future precision drugs have themselves made exciting advances towards the clinic.  New technologies and tools continue to revolutionise our understanding of cancer in the development of personalised and 'precision' drugs.  ValiRx continues to be at the forefront of these new developments in this space and I look forward to patients and shareholders alike benefiting from the Company's continued efforts to develop ground-breaking drugs and from the successful crystallisation of substantial value".

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

tarquin.edwards@valirx.com

 

 

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray/Jo Turner/Richard Nash

Tel: +44 (0) 20 7213 0880

 

 

Novum Securities Limited (Broker)

Colin Rowbury

Tel: +44 (0) 20 7399 9400

 

 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 

 

 

CHAIRMAN'S STATEMENT FOR THE HALF YEAR ENDED 30 JUNE 2018

During the period under review, I am pleased to report that our four therapeutic drugs in development, two of which are in clinical trials, have all taken significant strides forward along their respective clinical and pre-clinical pathways.  This is in line with the Company's aim to make a meaningful contribution in "precision" medicine and science, through the early detection of cancer and its personalised therapeutic intervention.   By so doing, ValiRx is striving to develop therapeutics that can substantially improve human health and well-being.

 

VAL401

A particularly pleasing achievement by the Company in the period was its successful completion of the VAL401 Phase ll clinical study in patients with late stage non-small cell lung cancer - the most common form of lung cancer.  Results from the trial show that palliative stage patients could expect to see improvements in quality of life, with the added benefit of improved survival prospects.  The encouraging 60% overall response rate provides a strong foundation for a pivotal Phase III clinical study and the measure of immune competency of the treated patients was also a pleasingly unexpected addition to the results. In summary, we are very excited to see such a good response rate for a condition with huge unmet medical need.

 

Detailed discussions are in progress in respect to a Phase III Clinical Trial and partners external to ValiRx and ValiSeek will have substantial input into the trial design with first dosing anticipated next year.

 

VAL201

VAL201 has performed extremely well in its clinical trials and has confirmed to date, that beyond it being well tolerated and safe, it is efficacious and works. The compound had a major trial review of its protocol at the end of 2017, which the regulatory authorities subsequently approved.  This modification to the trial protocol allows the Company to escalate or accelerate the dosing regimen of the study, from 4mg to 16mg in a couple of steps.  This effectively will see a substantial increase in the dose of VAL201 being administered to patients and allows treatment to more speedily reach its full therapeutic potential and potential anti-cancer impact on patients.

 

A post period preliminary inspection (announced 06/09/18) of the clinical data derived from the original dosing regimen has been completed regarding all the subjects that have been treated to date.  This inspection considered all dosing regimens.   In summary, the preliminary observations highlighted a dose-related impact on patients' physiology and chemistry, such as androgen PSA and various cell and protein turnover factors, which are important in the treatment of cancer.  These are in line with anticipated outcomes as far as cancer reduction is concerned.  Meanwhile, the Company continues to recruit appropriate patients for this second part of the trial.

 

VAL301

VAL301 is derived from our lead compound, VAL201 and is currently in late-stage pre-clinical development as a non-invasive, effective treatment for the non-cancerous, but hugely debilitating gynaecological condition, endometriosis.  We have established from our pre-clinical studies that VAL201's specific mode of action has the potential to provide a potent therapeutic effect to manage the symptoms of this hormonally-induced disorder, without side effects, including loss of bone density and/or infertility.

 

In preclinical studies, VAL301 has been shown to reduce endometrial lesions by up to 50% and the compound is well placed as a potential treatment.  VAL301 received a US patent grant for its use in endometriosis shortly after the period end and it is currently in final pre- clinical preparation with an ambition to move into the clinic within the next twelve months, dependant on funding and regulatory clearance.

 

GeneICE/VAL101

Shortly before the period under review, we announced another important breakthrough in the development of an optimised, commercially viable second generation of the VAL101 molecule derived from our proprietary GeneICE platform (announced 07/09/2017).  This molecule is based on a technology, which is called GeneICE ('Gene Inactivation by Chromatin Engineering') and is licensed from Imperial College.

 

Pre-clinical work being conducted with our partners, DKFZ, Heidelberg and Pharmatest in Finland, has generated a commercially viable molecular structure for VAL101.   The activity of Bcl-2, the gene associated with cancer, is seen to reduce and cancer cell death was seen to occur.  As such, ValiRx is currently accelerating VAL101's late pre-clinical studies in preparation for its entry into the clinic.

 

Outlook

The past six months have been a pivotal period for the Company as we have seen our two clinical stage compounds reach respective inflection points on their developmental pathways and our pre-clinical portfolio of future precision drugs have themselves made exciting advances towards the clinic.  New technologies and tools continue to revolutionise our understanding of cancer in the development of personalised and 'precision' drugs.  ValiRx continues to be at the forefront of these new developments in this space and I look forward to patients and shareholders alike benefiting from the Company's continued efforts to develop ground-breaking drugs and from the successful crystallisation of substantial value.

 

Oliver de Giorgio-Miller

Non-Executive Chairman

25 September 2018
 

Valirx Plc

Consolidated statement of comprehensive income

 

 

 

 

  Six months ended

 

  Six months ended

 

 

 

Note

30 June

 

30 June

 

31 December

 

 

 

2018

 

2017

 

2017

 

 

 

(unaudited)

 

(unaudited)

 

(audited)

 

 

 

£

 

£

 

£

 

 

 

 

 

 

 

 

 

 

 

 

 

(Note 7)

 

 

Revenue

 

 

                   -  

 

                   -  

 

                      -  

 

 

 

 

 

 

 

 

Cost of sales

 

 

                   -  

 

                   -  

 

                      -  

Gross profit

 

 

                   -  

 

                   -  

 

                      -  

 

 

 

 

 

 

 

 

Research and development

 

 

(851,688)

 

(723,149)

 

(1,746,808)

Administrative expenses

 

7

(920,760)

 

(761,008)

 

(1,467,268)

Share option charge

 

 

(332,241)

 

                    -  

 

                        -  

Other income

 

 

                   -  

 

                    -  

 

              88,773

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(2,104,689)

 

(1,484,157)

 

(3,125,303)

 

 

 

 

 

 

 

 

Fair value loss on derivative financial assets

 

 

(46,892)

 

(81,726)

 

(23,446)

Finance income

 

 

                   -  

 

               489

 

                   489

Fair value profit on derivative liability

 

 

                     -  

 

(204,346)

 

                 44,146

Finance costs

 

 

(207)

 

(284,471)

 

(449,868)

 

 

 

 

 

 

 

 

Loss before income taxation

 

 

(2,151,788)

 

(2,054,211)

 

(3,553,982)

 

 

 

 

 

 

 

 

Income tax credit

 

3

       206,000

 

        195,000

 

           416,336

 

 

 

 

 

 

 

 

Loss on ordinary activities after taxation

 

 

(1,945,788)

 

(1,859,211)

 

(3,137,646)

 

 

 

 

 

 

 

 

Non-controlling interests

 

 

         31,335

 

          59,119

 

           117,962

 

 

 

 

 

 

 

 

Loss for the period and total comprehensive income attributable to owners of the parent

 

 

(1,914,453)

 

(1,800,092)

 

(3,019,684)

 

 

 

 

 

 

 

 

Loss per share - basic and diluted

 

 

 

 

 

 

 

From continuing operations

 

4

(0.51)p

 

(1.57)p

 

(2.00)p

                 

 

 

 

 

Valirx Plc

Consolidated statement of changes in shareholders' equity

 

 

Share capital

 

Share premium

 

Retained earnings

 

Merger reserve

 

Share option reserve

 

Reverse acquisition reserve

 

 Non-controlling interest

 

 Total

 

£

 

£

 

£

 

£

 

£

 

£

 

£

 

£

Unaudited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 1 January 2018

8,432,708

 

  16,419,494

 

(23,378,744)

 

          637,500

 

           464,000

 

     602,413

 

(24,744)

 

   3,152,627

Loss for the period

              -  

 

                   -  

 

(1,914,453)

 

                      -  

 

                      -  

 

                 -  

 

(31,335)

 

(1,945,788)

Issue of shares

  104,653

 

   2,354,512

 

                    -  

 

                      -  

 

                      -  

 

                 -  

 

                 -  

 

   2,459,165

Costs of shares issued

              -  

 

(239,853)

 

                   -  

 

                      -  

 

                      -  

 

                 -  

 

                  -  

 

(239,853)

Exercise of share options and warrants

-

 

          147,394

 

                       -  

 

                          -  

 

(147,394)

 

                     -  

 

                     -  

 

                     -   

Lapse of share options

             -  

 

                  -  

 

            2,400

 

                      -  

 

(2,400)

 

                 -  

 

                 -  

 

                 -  

Share based payment

             -  

 

                  -  

 

                   -  

 

                      -  

 

           394,094

 

                 -  

 

                  -  

 

      394,094

Balance at 30 June 2018

8,537,361

 

 18,681,547

 

(25,290,797)

 

          637,500

 

           708,300

 

     602,413

 

(56,079)

 

  3,820,245

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unaudited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 1 January 2017

8,165,650

 

 12,998,102

 

(20,385,278)

 

          637,500

 

           331,453

 

     602,413

 

        19,619

 

  2,369,459

Loss for the period

              -  

 

                   -  

 

(1,800,092)

 

                      -  

 

                      -  

 

                  -  

 

(59,119)

 

(1,859,211)

On acquisition of subsidiary assets

                 -  

 

                      -  

 

                       -  

 

                          -  

 

                          -  

 

                     -  

 

            55,303

 

            55,303

Issue of shares

    60,557

 

   1,478,947

 

                   -  

 

                      -  

 

                      -  

 

                 -  

 

                 -  

 

  1,539,504

Costs of shares issued

              -  

 

(307,505)

 

                   -  

 

                      -  

 

                      -  

 

                 -  

 

                  -  

 

(307,505)

Share based payment

             -  

 

                  -  

 

                   -  

 

                      -  

 

           197,332

 

                 -  

 

                 -  

 

     197,332

Balance at 30 June 2017

8,226,207

 

 14,169,544

 

(22,185,370)

 

          637,500

 

           528,785

 

     602,413

 

15,803

 

  1,994,882

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Audited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 1 January 2017

8,165,650

 

  12,998,102

 

(20,385,278)

 

          637,500

 

           331,453

 

     602,413

 

        19,619

 

  2,369,459

Loss for the year

             -  

 

                  -  

 

(3,019,684)

 

                      -  

 

                      -  

 

                 -  

 

(117,962)

 

(3,137,646)

On acquisition of subsidiary assets

                 -  

 

                      -  

 

                       -  

 

                          -  

 

                          -  

 

                     -  

 

            73,599

 

            73,599

Issue of shares

   267,058

 

    3,866,468

 

                   -  

 

                      -  

 

                      -  

 

                 -  

 

                  -  

 

    4,133,526

Costs of shares issued

             -  

 

(445,076)

 

                   -  

 

                      -  

 

                      -  

 

                 -  

 

                 -  

 

(445,076)

Lapse of share options

             -  

 

                  -  

 

         26,218

 

                      -  

 

(26,218)

 

                 -  

 

-

 

                  -  

Share based payment

             -  

 

                  -  

 

                   -  

 

                      -  

 

           158,765

 

                 -  

 

                 -  

 

      158,765

Balance at 31 December 2017

8,432,708

 

16,419,494

 

(23,378,744)

 

          637,500

 

           464,000

 

     602,413

 

(24,744)

 

  3,152,627

 

 

 

Valirx Plc

Consolidated statement of financial position

 

 

 

As at 30 June

 

31 December

 

 

2018

 

2017

 

2017

 

 

(unaudited)

 

(unaudited)

 

(audited)

 

 

£

 

£

 

£

ASSETS

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

Goodwill

 

     1,602,522

 

        1,584,227

 

        1,602,522

Intangible assets

 

     1,379,876

 

        1,363,833

 

        1,325,283

Property, plant and equipment

 

                    -  

 

                5,273

 

                       -  

 

 

 

 

 

 

 

 

 

     2,982,398

 

        2,953,333

 

        2,927,805

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Trade and other receivables

 

        746,532

 

          698,038

 

            766,475

Tax receivable

 

        257,244

 

          839,497

 

            424,094

Derivative financial assets

 

          70,338

 

            58,949

 

            117,229

Cash and cash equivalents

 

        590,615

 

          383,426

 

            701,410

 

 

        1,664,729

 

           1,979,910

 

           2,009,208

 

 

 

 

 

 

 

Total assets

 

    4,647,127

 

        4,933,243

 

        4,937,013

 

 

 

 

 

 

 

SHAREHOLDERS' EQUITY

 

 

 

 

 

 

Share capital

 

     8,537,361

 

        8,226,207

 

        8,432,708

Share premium account

 

  18,681,547

 

        14,169,544

 

      16,419,494

Merger reserve

 

        637,500

 

           637,500

 

            637,500

Reverse acquisition reserve

 

        602,413

 

           602,413

 

            602,413

Share option reserve

 

        708,300

 

           528,785

 

            464,000

Retained earnings

 

(25,290,797)

 

(22,185,370)

 

(23,378,744)

 

 

 

 

 

 

 

 

 

     3,876,324

 

        1,979,079

 

        3,177,371

Non-controlling interest

 

(56,079)

 

             15,803

 

(24,744)

 

 

 

 

 

 

 

Total equity

 

     3,820,245

 

        1,994,882

 

        3,152,627

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Trade and other payables

 

        826,882

 

        1,564,313

 

1,394,266

Borrowings

 

                    -  

 

        1,125,556

 

            390,120

Derivative liability

 

                    -  

 

           248,492

 

                       -  

 

 

        826,882

 

        2,938,361

 

        1,784,386

 

 

 

 

 

 

 

Total equity and liabilities

 

     4,647,127

 

        4,933,243

 

        4,937,013

 

 

 

Valirx Plc

Consolidated cash flow statement

 

 

 

Six months ended 30 June

 

31 December

 

 

2018

 

2017

 

2017

 

 

(unaudited)

 

(unaudited)

 

(audited)

 

 

£

 

£

 

£

Cash flows from operating activities

 

 

 

 

 

 

Operating loss

 

(2,104,689)

 

(1,484,157)

 

(3,125,303)

Depreciation of property plant and equipment

 

                    -  

 

                5,280

 

              10,553

Amortisation of intangible assets

 

          84,800

 

             46,300

 

            177,134

(Increase)/decrease in receivables

 

(25,005)

 

             82,904

 

              14,467

(Decrease)/increase in payables within one year

 

(567,384)

 

           284,002

 

              54,038

Other non-cash movements

 

43,991

 

(61,922)

 

(83,164)

Share option charge

 

        332,342

 

           197,332

 

                       -  

 

 

 

 

 

 

 

 

 

(2,235,945)

 

(930,261)

 

(2,952,275)

Tax credit received

 

        372,850

 

                       -  

 

            636,739

Interest paid

 

(207)

 

(18,341)

 

(35,897)

 

 

 

 

 

 

 

Net cash outflow from operating activities

 

(1,863,302)

 

(948,602)

 

(2,351,433)

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

Purchase of goodwill

 

                    -  

 

(55,303)

 

(73,599)

Purchase of intangible assets

 

(139,393)

 

(114,444)

 

(206,727)

Non-controlling interests

 

                    -  

 

             55,303

 

              73,599

Interest received

 

                    -  

 

                  489

 

                   489

 

 

 

 

 

 

 

Net cash outflow from investing activities

 

(139,393)

 

(113,955)

 

(206,238)

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

Share issue

 

    2,070,000

 

       1,192,725

 

       3,068,406

Costs of shares issued

 

(178,100)

 

(307,505)

 

(286,311)

New convertible loan notes

 

                   -  

 

                       -  

 

            263,704

Repayment of convertible loan notes

 

                   -  

 

                       -  

 

(347,481)

 

 

 

 

 

 

 

Net cash generated from financing activities

 

    1,891,900

 

           885,220

 

        2,698,318

 

 

 

 

 

 

 

Net (decrease)/increase in cash and cash equivalents

 

(110,795)

 

(177,337)

 

               140,647

 

 

 

 

 

 

 

Cash and cash equivalents at start of period

 

       701,410

 

          560,763

 

            560,763

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

       590,615

 

          383,426

 

            701,410

 

 

 

 

Valirx Plc

Notes to the interim financial statements

1              General information

Valirx Plc is a company incorporated in the United Kingdom, which is listed on the Alternative Investment Market of the London Stock Exchange Plc. The address of its registered office is 3rd Floor, 16 Upper Woburn Place, London WC1H 0BS

2              Financial information

The interim consolidated financial information for the six months ended 30 June 2018 has not been audited or reviewed and does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. The Group's statutory accounts for the year ended 31 December 2017 have been delivered to the Registrar of Companies. The report of the independent auditors on those financial statements was unqualified and did not contain a statement under Sections 498 (2) or (3) of the Companies Act 2006.

 

The interim financial statements have been prepared in accordance with International Financial Reporting Standards ('IFRS') as adopted by the European Union, IFRIC interpretations and the Companies Act 2006 applicable to companies reporting under IFRS and under the historical cost convention. The accounting policies applied in preparing the interim financial information are consistent with those set out in the statutory accounts of the Company for the year ended 31 December 2017.

 

The interim consolidated financial statements are presented in pounds sterling because that is the currency of the primary economic environment in which the group operates.

 

3              Taxation

 

 

  Six months ended

 

  Six months ended

 

Year ended

 

 

30 June

 

30 June

 

31 December

 

 

2018

 

2017

 

2017

 

 

(unaudited)

 

(unaudited)

 

(audited)

 

 

£

 

£

 

£

United Kingdom corporation tax at 20%

 

 

 

 

 

 

  Current period - R & D Tax credit

 

(206,000)

 

(195,000)

 

(424,094)

  Prior period - R & D Tax credits

 

                 -  

 

                    -  

 

              7,758

 

 

 

 

 

 

 

Income tax credit

 

(206,000)

 

(195,000)

 

(416,336)

 

4              Loss per ordinary share

The loss and number of shares used in the calculation of loss per share are as follows:

 

 

  Six months ended

 

  Six months ended

 

Year ended

 

 

30 June

 

30 June

 

31 December

 

 

2018

 

2017

 

2017

 

 

(unaudited)

 

(unaudited)

 

(audited)

Basic:

 

 

 

 

 

 

Loss for the financial period

 

(1,945,788)

 

(1,859,211)

 

(3,137,646)

Non-controlling interest

 

             31,335

 

                59,119

 

               117,962

 

 

 

 

 

 

 

 

 

(1,914,453)

 

(1,800,092)

 

(3,019,684)

 

 

 

 

 

 

 

Weighted average number of shares

 

   384,343,833

 

      114,718,325

 

       151,071,019

Loss per share  - continuing operations

 

(0.51)p

 

(1.57)p

 

(2.00)p

 

The outstanding share options and share warrants would have no dilutive effect on the loss per share.

 

5              Dividends

The directors do not propose to declare a dividend in respect of the period.

 

6              Share capital

 

 

30 June 2018

 

30 June 2017

 

Number

 

 £

 

Number

 

 £

 

(unaudited)

 

(unaudited)

 

(unaudited)

 

(unaudited)

Allotted, called up and fully paid

 

 

 

 

 

 

 

Ordinary shares of 0.1p each

454,962,717

 

       454,963

 

143,809,745

 

       143,809

Deferred shares of 5.0p each

 58,378,365

 

    2,918,918

 

58,378,365

 

     2,918,918

Deferred shares of 0.9p each

157,945,030

 

    1,421,505

 

157,945,030

 

    1,421,505

Deferred shares of 12.4p each

 30,177,214

 

    3,741,974

 

  30,177,214

 

    3,741,974

 

 

 

      8,537,361

 

 

 

       8,226,206

 

 

 

 

 

 

 

 

 

31 December 2017

 

 

 

 

 

Number

 

 £

 

 

 

 

Allotted, called up and fully paid

(unaudited)

 

(unaudited)

 

 

 

 

Ordinary shares of 0.1p each

350,310,448

 

         350,311

 

 

 

 

Deferred shares of 5.0p each

58,378,365

 

      2,918,918

 

 

 

 

Deferred shares of 0.9p each

157,945,030

 

       1,421,505

 

 

 

 

Deferred shares of 12.4p each

30,177,214

 

3,741,974

 

 

 

 

 

 

 

     8,432,708

 

 

 

 

 

·              On 2 January 2018, the Company raised £1.0 million, before expenses, by way of a placing of 23,529,412 ordinary shares of 0.1p each at a price of 4.25p per share;

·              On 3 January 2018, the Company converted US$520,000 of Convertible Loan Notes (plus accrued interest of US$1,667) into 25,222,857 ordinary shares of 0.1p each at a price of 1.5429p per share:

·              On 8 January 2018, warrants were exercised over 8,000,000 shares and 400,000 shares at exercise prices of 1.25p and 5p respectively, raising gross proceeds of £120,000.

·              On 14 May 2018, the Company raised £0.95 million, before expenses, by way of a placing of 47,500,000 ordinary shares of 0.1p each at a price of 2.00p per share;

 

7              Comparative figures for the unaudited accounts for the six months ended 30 June 2017

As the warrants issued during the six months ended 30 June 2017 were all in consideration of shares issued, the charge should have been taken directly to equity and charged against the share premium as costs in respect of the shares issued rather than the statement of comprehensive income. The effect of this adjustment is to reduce the loss for the six months ended 30 June by £197,332 and to reduce the share premium account by a like amount. There is no impact on the total assets of the Group.

 

There is no impact on either the audited accounts for the year ended 31 December 2017 or the unaudited accounts for the six months ended 30 June 2018.

 

8              Copies of interim results

Copies of the interim results can be obtained from the website www.valirx.com. From this site you may access our financial reports and presentations, recent press releases and details about the company and its operations.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IR BRGDCDUDBGIS